AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2026. Recent Financial Highlights Generated total revenues of $794.0 million in the third quarter of 2026, compared to $592.2 million in the third quarter of 2025, an increase of 34.1%. Generated a gross margin1 of 64.7% in the third quarter of 2026, compared to a gross margin1 of 64.9% in the third q
